Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function.
Rachel D HarrisOlga A TaylorKimberly P RaghubarMaria Monica J GramatgesMark C ZobeckM Monica GramatgesKaren R RabinMichael E ScheurerAustin L BrownPublished in: Pediatric blood & cancer (2024)
Methotrexate is a critical component of curative chemotherapy for pediatric acute lymphoblastic leukemia (ALL), but is associated with neurotoxicity. Information on long-term outcomes following an acute neurotoxic event is limited. Therefore, this report compares neurocognitive performance more than 12 months post diagnosis (mean = 4 years) between ALL patients with (n = 25) and without (n = 146) a history of acute neurotoxicity. Compared to children with no documented on-treatment neurotoxic event, children who experienced a neurotoxic event during treatment exhibited poorer performance on measures of fine motor function (p = .02) and attention (p = .02). Children with ALL who experience acute neurotoxicity may be candidates for early neuropsychological screening and intervention.
Keyphrases
- liver failure
- respiratory failure
- acute lymphoblastic leukemia
- drug induced
- young adults
- aortic dissection
- randomized controlled trial
- high dose
- hepatitis b virus
- squamous cell carcinoma
- air pollution
- healthcare
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- radiation therapy
- intensive care unit
- replacement therapy
- childhood cancer